A Phase 2 Randomized Trial of Caloric Restriction and Activity to Reduce Chemoresistance in B-cell Acute Lymphoblastic Leukemia

Who is this study for? Patients with B-cell Acute Lymphoblastic Leukemia, Obesity
What treatments are being studied? IDEAL2 Intervention
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 25
Healthy Volunteers: f
View:

• Patients must be ≥ 10.0 and \<26.0 years of age.

• Patients must have a diagnosis of de novo B-ALL

• Patients must have a M3 marrow (\>25% blasts by morphology) or at least 1,000/µL circulating leukemia cells in PB confirmed by Flow Cytometry (or other convincing evidence of a B-ALL diagnosis not meeting above criteria following central review by the Study Hematopathologist and Study Chair or Vice-Chair).

• The treatment regimen must be the first treatment attempt for B-ALL-

• Must be a multi-agent induction regimen inclusive of vincristine, glucocorticoid, pegaspargase/calaspargase, and daunorubicin or doxorubicin and with a planned duration \<35 days.

• Organ function must meet that required for initiation of chemotherapy

• Patients at diagnosis must meet Karnofsky \> 50% for patients \> 16 years of age and Lansky \> 50% for patients ≤ 16 years of age (or be expected to recover prior to Day 8) .

• If the patient is a female of childbearing potential, a negative urine or serum pregnancy test is required within two weeks prior to enrollment.

Locations
United States
California
Children's Hospital Los Angeles
RECRUITING
Los Angeles
Children's Hospital Orange County
RECRUITING
Orange
UCSF School of Medicine
RECRUITING
San Francisco
Colorado
Colorado Children's Hospital
RECRUITING
Denver
Georgia
Children's Healthcare of Atlanta at Egleston
NOT_YET_RECRUITING
Atlanta
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING
Chicago
Maryland
Johns Hopkins / Sydney Kimmel Cancer Center
NOT_YET_RECRUITING
Baltimore
Michigan
C.S. Mott University of Michigan
RECRUITING
Ann Arbor
Minnesota
Children's Hospitals and Clinics of Minnesota
RECRUITING
Minneapolis
North Carolina
Levine Children's Hospital
RECRUITING
Charlotte
New York
Columbia University Medical Center
NOT_YET_RECRUITING
New York
Ohio
Cincinnati Children's Hospital Medical Center
NOT_YET_RECRUITING
Cincinnati
Nationwide Children's Hospital
NOT_YET_RECRUITING
Columbus
Oregon
Oregon Health & Science University
NOT_YET_RECRUITING
Portland
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
Texas
University of Texas, Southwestern
RECRUITING
Dallas
Cook Children's Medical Center
NOT_YET_RECRUITING
Fort Worth
Baylor Texas Children's Hospital
RECRUITING
Houston
Utah
Primary Children's Hospital
RECRUITING
Salt Lake City
Wisconsin
Children's Hospital of Wisconsin
NOT_YET_RECRUITING
Milwaukee
Contact Information
Primary
Ellynore Florendo
eflorendo@chla.usc.edu
323-361-3022
Backup
Roy Leong
rleong@chla.usc.edu
323-361-5132
Time Frame
Start Date: 2022-03-12
Estimated Completion Date: 2031-10-15
Participants
Target number of participants: 240
Treatments
Experimental: IDEAL2 intervention
Focused and short-term intervention of diet and exercise during induction. Calorie goal is \>=15% daily deficit as determined by each subject's estimated energy requirement. Fat intake will make up \<25% of daily calories. Carbohydrate will make up \<55% of daily calories consisting of low glycemic load foods (\<100/2,000 kcal adjusted for daily calories). Protein will make up \>=20% of daily calories. Subjects will also perform moderate exercise 5 days per week for 30 minutes/session (total = 150 minutes per week). Subjects will have a step goal to decrease sedentary behavior, with a starting goal of \>=1000 steps/day and increasing by at least 1000 steps/day each week.
No_intervention: Control - Standard of Care
One-time education of diet and exercise, which is the standard of care for ALL patients during induction.
Sponsors
Leads: Etan Orgel
Collaborators: Therapeutic Advances in Childhood Leukemia Consortium

This content was sourced from clinicaltrials.gov

Similar Clinical Trials